The Europe hyaluronic acid-based dermal fillers market was estimated at USD 1.18 billion in 2023 and it is expected to surpass around USD 2.83 billion by 2033, poised to grow at a CAGR of 9.14% from 2024 to 2033.
The Europe hyaluronic acid-based dermal fillers market is driven by various factors such as increasing demand for minimally invasive cosmetic procedures, rising awareness about anti-aging treatments, and advancements in dermal filler technology.
The growth of the Europe hyaluronic acid-based dermal fillers market is driven by growing trend towards minimally invasive cosmetic procedures among the aging population seeking to maintain a youthful appearance without undergoing surgery. Hyaluronic acid-based fillers offer a safe and effective solution for addressing various signs of aging, such as wrinkles and volume loss, further driving market demand. Additionally, advancements in dermal filler technology have led to the development of more versatile and long-lasting products, enhancing their appeal to both patients and healthcare professionals. Moreover, increasing awareness about the benefits of hyaluronic acid-based fillers, including their natural-looking results and minimal downtime, is fueling market growth.
Report Coverage | Details |
Market Size in 2023 | USD 1.18 billion |
Revenue Forecast by 2033 | USD 2.83 billion |
Growth rate from 2024 to 2033 | CAGR of 9.14% |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Based on application, the Europe hyaluronic acid-based dermal fillers market is segmented into wrinkle removal, lip augmentation, rhinoplasty, and others. The wrinkle removal segment held the largest market share of 30% in 2023 and is also expected to grow at the fastest CAGR of 8.35% over the forecast period. Hyaluronic acid fillers are gaining popularity in varied antiaging treatments. The increasing need and impulse to look young and defer the effects of aging have led to the advancement in technology, resulting in non-invasive procedures for the treatment of wrinkles.
Hyaluronic acid fillers are time-saving procedures that require no bandages or incisions and impose no restrictions after completion of the procedure. These act as substitutes for injectable fillers such as collagen because they are relatively less expensive, have a negligible risk of allergic reaction, and are more comfortable compared to injectable fillers.
The market in Europe can be broadly studied based on product into single-phase products and duplex products. Single-phase products accounted for around 52% share in 2023 and are expected to grow at the fastest CAGR over the forecast period. This is owing to technological advancements, a wide range of applications, increasing government funding for innovation, and a rise in applications of implantable devices.
Hylacross technology provides a high concentration of cross-linked hyaluronic acid molecules, resulting in the longevity of desirable effects. These are utilized for volumizing and correcting deeper folds, leading to more preferability. Desired and beneficial effects produced by single-phase products are leading to an increase in their preference among consumers.
Dermal fillers market growth has been considerably influenced by increased per capita spending on cosmetics and rising awareness of aesthetic procedures through various platforms. Personal care costs have increased due to changing human behaviors and lifestyles, rising incomes, and concern for beauty. As the population ages and people's interest in aesthetics increases, demand for dermal fillers will continue to rise. The growing popularity of aesthetic operations results from technology advancements and a wider variety of procedures being offered. Dermal fillers and other therapies and surgical and non-surgical procedures are now available to patients.
By Product
By Application
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Europe Hyaluronic Acid-based Dermal Fillers Market
5.1. COVID-19 Landscape: Europe Hyaluronic Acid-based Dermal Fillers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Europe Hyaluronic Acid-based Dermal Fillers Market, By Product
8.1. Europe Hyaluronic Acid-based Dermal Fillers Market, by Product, 2024-2033
8.1.1. Single-phase Products
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Duplex Products
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Europe Hyaluronic Acid-based Dermal Fillers Market, By Application
9.1. Europe Hyaluronic Acid-based Dermal Fillers Market, by Application, 2024-2033
9.1.1. Wrinkle Removal
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Lip Augmentation
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Rhinoplasty
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Europe Hyaluronic Acid-based Dermal Fillers Market, Regional Estimates and Trend Forecast
10.1. Europe
10.1.1. Market Revenue and Forecast, by Product (2021-2033)
10.1.2. Market Revenue and Forecast, by Application (2021-2033)
Chapter 11. Company Profiles
11.1. Allergan
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Galderma Laboratories
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Merz Pharma
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Genzym corporation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Medicis Pharmaceutical (Bausch Health)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Inamed Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Laboratoires VIVACY
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bioxis Pharmaceuticals
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms